The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $520,351 in first-year total cost, median $260,176.
Most frequent study sections
- Special Emphasis Panel[ZAR1 YL (M1)]1
- Special Emphasis Panel[ZAR1 YL (M2)]1
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Utilizing the RA signature to predict TNFi response1R21AR074788-01 | HO, I-CHENG | BRIGHAM AND WOMEN'S HOSPITAL, MA | $315,040 | ZAR1 |
| 2018 | Skeletal survivorship and immune therapy: The effects of nivolumab on bone metabolism in renal cell carcinoma1R21AR073620-01 | MOSELEY, KENDALL | JOHNS HOPKINS UNIVERSITY, MD | $205,311 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.